Promising results reported with combination immunotherapy for glioblastoma

A novel approach to immunotherapy may improve outcomes in patients with newly diagnosed glioblastoma (ND-GBM), new data suggest.

“Despite decades of research, no significant change in survival has been made in GBM”, according to Dr David Reardon of the Dana-Farber Cancer Institute in Boston, Massachusetts, USA. “And despite advances with immune checkpoint inhibitors in other cancers, there has been no significant improvement in survival compared to historical controls in ND-GBM.”

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.